Your browser is no longer supported. Please, upgrade your browser.
Settings
EIGR Eiger BioPharmaceuticals, Inc. daily Stock Chart
EIGR [NASD]
Eiger BioPharmaceuticals, Inc.
Index- P/E- EPS (ttm)-5.69 Insider Own0.40% Shs Outstand8.78M Perf Week-3.03%
Market Cap112.38M Forward P/E- EPS next Y-4.94 Insider Trans74.55% Shs Float7.95M Perf Month21.33%
Income-46.50M PEG- EPS next Q-1.28 Inst Own69.00% Short Float1.65% Perf Quarter35.45%
Sales- P/S- EPS this Y87.40% Inst Trans1.03% Short Ratio2.19 Perf Half Y63.06%
Book/sh2.47 P/B5.18 EPS next Y5.20% ROA-88.90% Target Price32.40 Perf Year-11.05%
Cash/sh4.59 P/C2.79 EPS next 5Y- ROE-128.90% 52W Range6.10 - 14.75 Perf YTD9.87%
Dividend- P/FCF- EPS past 5Y-25.60% ROI- 52W High-13.22% Beta2.59
Dividend %- Quick Ratio7.00 Sales past 5Y- Gross Margin- 52W Low109.84% ATR0.75
Employees17 Current Ratio7.00 Sales Q/Q- Oper. Margin- RSI (14)60.78 Volatility7.85% 5.71%
OptionableNo Debt/Eq0.00 EPS Q/Q28.70% Profit Margin- Rel Volume2.03 Prev Close12.25
ShortableYes LT Debt/Eq0.72 EarningsNov 13 AMC Payout- Avg Volume59.80K Price12.80
Recom1.20 SMA206.56% SMA5024.05% SMA20033.86% Volume121,527 Change4.49%
Oct-19-17Initiated ROTH Capital Buy $35
Jun-21-17Resumed Wedbush Outperform $28 → $34
Oct-02-17 08:00AM  Eiger Announces Abstracts and Presentations at the American Association for the Study of Liver Diseases (AASLD) Meeting PR Newswire +6.36%
Sep-18-17 08:00AM  Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors PR Newswire
Sep-05-17 08:00AM  Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection PR Newswire
Aug-30-17 08:00AM  Eiger BioPharmaceuticals to Present at Two Upcoming Investor Conferences PR Newswire +9.39%
Aug-14-17 11:22PM  Eiger BioPharma reports 2Q loss Associated Press
08:00AM  Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results PR Newswire
Aug-08-17 08:00AM  Eiger BioPharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference on August 16th PR Newswire
Jul-27-17 08:00AM  Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection PR Newswire
Jul-24-17 08:00AM  Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection PR Newswire
Jul-17-17 08:30AM  Eiger BioPharmaceuticals (EIGR) Rises: Stock Climbs 24% Zacks +7.57%
Jun-29-17 08:00AM  Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals PR Newswire +10.71%
Jun-14-17 08:00AM  Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors PR Newswire
Jun-12-17 08:00AM  Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego PR Newswire
Jun-06-17 08:00AM  Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients PR Newswire
May-30-17 08:00AM  Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th PR Newswire
May-17-17 08:00AM  Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema PR Newswire
May-15-17 08:00AM  Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension PR Newswire
May-12-17 08:15AM  Eiger BioPharma reports 1Q loss Associated Press -6.62%
08:00AM  Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results PR Newswire
May-08-17 08:00AM  Eiger Announces Presentation of Prevalence Data of Hepatitis Delta Virus (HDV) Infection in the U.S. at Digestive Disease Week (DDW) in Chicago PR Newswire
May-04-17 08:00AM  Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City PR Newswire
May-03-17 08:00AM  Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection PR Newswire
Apr-30-17 02:00PM  2 'Swing for the Fences' Small Biotechs TheStreet.com
Apr-24-17 08:00AM  Eiger Announces Abstract and Presentation at 2017 Digestive Disease Week in Chicago PR Newswire
Apr-21-17 08:00AM  Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress 2017 PR Newswire
Apr-18-17 08:00AM  Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia PR Newswire
Apr-06-17 08:00AM  Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) Meeting PR Newswire -15.74%
Mar-28-17 01:04PM  EIGER BIOPHARMACEUTICALS, INC. Financials
09:50AM  New Strong Buy Stocks for March 28th
Mar-23-17 08:10AM  Eiger BioPharma reports 4Q loss Associated Press
08:04AM  EIGER BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
08:00AM  Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results PR Newswire
06:06AM  EIGER BIOPHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
Mar-06-17 08:00AM  Eiger BioPharmaceuticals to Present at the ROTH and Oppenheimer Investor Conferences in March 2017 PR Newswire
Jan-30-17 08:00AM  Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th PR Newswire
Jan-05-17 04:08PM  EIGER BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct F
Jan-04-17 08:00AM  Eiger Completes $25 Million Debt Financing with Oxford Finance PR Newswire
Jan-03-17 08:00AM  Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH) PR Newswire
Dec-14-16 06:21PM  How Five Star Quality Care, Inc. (FVE) Stacks Up Against Its Peers Insider Monkey
Dec-12-16 08:00AM  Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH) PR Newswire
Dec-01-16 08:44AM  Eiger BioPharmaceuticals, Inc. :EIGR-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016 Capital Cube
Nov-29-16 08:00AM  Eiger Updates Progress in Clinical Development Program for Exendin 9-39 to Treat Post-Bariatric Hypoglycemia (PBH) PR Newswire
Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. It portfolio of products include Sarasar, an indication for the hepatitis delta virus infection; Exendin, which is used for the treatment of hypoglycemia associated with bariatric surgery; and Bestatin that is used for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. The company was founded in 2008 and is headquartered in Palo Alto, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Glenn Jeffrey SDirectorSep 01Buy9.5315,000142,95031,355Sep 05 06:20 PM